| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology and medicine, and concerns an vaccine against influenza caused by known viral strains of influenza A and B, as well as potential reassortants. The presented polyvalent influenza vaccine is based on a hybrid protein containing N1, N3 and N5 protein fragments of influenza A virus, a haemagglutinin fragment of influenza B virus and FliC1 and FliC2 flagellin components (SEQ ID NO:1) bridged flexibly. The protein-coding nucleotide sequence (SEQ ID NO:2) is optimised for the high expression in Escherichia coli cells.EFFECT: using the characterised vaccine enables providing the general protection against influenza.3 cl, 4 dwg, 1 tbl, 13 ex |
